Donepezil and Memantine for Moderate to Severe Alzheimers Disease

For the first time, we have robust and compelling evidence that treatment with these drugs can continue to help patients at the later, more severe stages of the disease. We observed that patients who continued taking donepezil were better able to remember, understand, communicate and perform daily tasks for at least a year longer than those who stopped taking the drugs.
-- Professor Robert Howard

Read more in the Alzheimers Reading Room

http://www.alzheimersreadingroom.com/2012/03/donepezil-and-memantine-for-moderate-to.html

Alzheimers group seeks $2 billion a year for research

Finding a cure or way to slow down the progression of the disease would require $2 billion in yearly funds, said William Thies, chief medical and scientific officer for the Alzheimer's Association.

"Without the spending in that range ($2 billion), we're not going to see the progress we need to see," he said. He adds that the last successful research to find a treatment for a symptom of the disease was in 2003. "You can't make progress with the sort of investments made to date."

The National Institute on Aging is holding a May summit to gather expert input for research priorities. Among those expected to attend, Thies said, are 16 highly esteemed researchers who developed the $2 billion price tag for research.

Read more about Alzheimers and dementia at the Alzheimer's Reading Room

http://www.alzheimersreadingroom.com/2010/02/about-alzheimers-reading-room.html